3//SEC Filing
Sofinnova Venture Partners X, L.P. 3
Accession 0001104659-21-012449
CIK 0001641281other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 8:59 PM ET
Size
21.0 KB
Accession
0001104659-21-012449
Insider Transaction Report
Form 3
Sofinnova Venture Partners X, L.P.
10% Owner
Holdings
Series C-1 Preferred Stock
Exercise: $0.00→ Common Stock (1,104,209 underlying)Series C-2 Preferred Stock
Exercise: $0.00→ Common Stock (1,200,228 underlying)
Katabi Maha
10% Owner
Holdings
Series C-1 Preferred Stock
Exercise: $0.00→ Common Stock (1,104,209 underlying)Series C-2 Preferred Stock
Exercise: $0.00→ Common Stock (1,200,228 underlying)
POWELL MICHAEL
10% Owner
Holdings
Series C-1 Preferred Stock
Exercise: $0.00→ Common Stock (1,104,209 underlying)Series C-2 Preferred Stock
Exercise: $0.00→ Common Stock (1,200,228 underlying)
Sofinnova Management X, L.L.C.
10% Owner
Holdings
Series C-1 Preferred Stock
Exercise: $0.00→ Common Stock (1,104,209 underlying)Series C-2 Preferred Stock
Exercise: $0.00→ Common Stock (1,200,228 underlying)
Footnotes (3)
- [F1]The Series C-1 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. The shares of Series C-1 Preferred Stock will automatically convert into shares of Common Stock of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer (the "IPO").
- [F2]The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
- [F3]The Series C-2 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. The shares of Series C-2 Preferred Stock will automatically convert into shares of Common Stock of the Issuer on a 1-to-1 basis upon closing of the IPO.
Issuer
Bolt Biotherapeutics, Inc.
CIK 0001641281
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001680200
Filing Metadata
- Form type
- 3
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 8:59 PM ET
- Size
- 21.0 KB